Table 5 Diagnosis, treatment, and response to therapeutics in 30 renal transplant recipients with post-transplantation visceral leishmaniasis
Variable | n(%) | P-value * |
|---|---|---|
VL diagnosis | ||
Direct identification of the parasite | 22 (73.3) | 0.016 |
Indirect method (immunological) | 8 (26.7) | |
Myelogram | ||
Yes | 19 (63.3) | 0.011 |
No | 11 (26.7) | |
Antigen rk39 isolation | ||
Yes | 5 (16.7) | 0.000 |
No | 25 (83.3) | |
PCR | ||
Yes | 1 (3.3) | 0.000 |
No | 29 (96.7) | |
Spleen biopsy | ||
Yes | 2 (6.7) | 0.000 |
No | 28 (23.3) | |
Use of amphotericin | ||
Liposomal amphotericin B | 28 (93.3) | 0.000 |
Amphotericin B | 2 (6.7) | |
Use of N-methylglucamine | ||
Yes | 7 (23.3) | 0.005 |
No | 21 (66.7) | |
VL relapse | ||
Yes | 8 (26.7) | 0.016 |
No | 22 (73.3) | |
Patients with VL remission | ||
Yes | 24 (80.0) | 0.001 |
No | 6 (20.0) | |
Deceased patients | ||
Yes | 5 (16.7) | 0.000 |
No | 25 (83.3) | |
Patients with VL remission and graft loss | ||
Yes | 10 (33.3) | 0.099 |
No | 20 (66.7) | |
Patients with VL remission and graft dysfunction | ||
Yes | 22 (73.3) | 0.016 |
No | 8 (26.7) | |
Patients with VL remission and return to dialysis | ||
Yes | 10 (33.3) | 0.099 |
No | 20 (66.7) |